Reaction
Immune-Mediated Renal Disorder reporting signals
As of the last recalculation, Immune-Mediated Renal Disorder appears in 386 FAERS reports alongside 12 co-occurring drug terms. The strongest observed disproportionality signal is PEMBROLIZUMAB (PRR 338.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Pembrolizumab | 244 | 338.2 | 339.0 |
| Ipilimumab | 53 | 76.6 | 76.7 |
| Nivolumab | 95 | 70.0 | 70.0 |
| Durvalumab | 19 | 52.9 | 53.0 |
| Pemetrexed Disodium | 33 | 51.0 | 51.0 |
| Pemetrexed | 16 | 41.9 | 42.0 |
| Carboplatin | 67 | 34.2 | 34.2 |
| Axitinib | 10 | 28.4 | 28.4 |
| Lenvatinib | 16 | 27.4 | 27.4 |
| Cisplatin | 36 | 27.3 | 27.3 |
| Paclitaxel (Aibumin-Bound) | 36 | 25.9 | 26.0 |
| Paclitaxel | 42 | 25.5 | 25.5 |